ERBB2 amplification in breast cancer with a high rate of proliferation.

摘要: The ERBB2 proto-oncogene was studied in 539 invasive primary breast tumors and found amplified (2- greater than 30 copies) 19%. Amplification correlated to most known risk factors, including; large tumor size, lymph node positivity many involved nodes, advanced stage, low patient age (less 40 years), non-diploidy hypertetraploidy, significantly (P less 0.00001) the absence of steroid receptors a high rate proliferation (flow cytometric determined S phase fraction). amplification strongly associated 0.0001) with early recurrence death cancer among node-positive patients. This connection did not, however, remain multivariate analyses. No correlations clinical outcome were seen node-negative Similarly, non-diploid, but not diploid, particularly aggressive. Furthermore, poor prognosis receptor positive, negative tumors. In progesterone positive cancer, an independent status equally powerful predictor survival. It is concluded that activity related increased growth directly metastasizing ability. Its relevance as prognostic factor may be selecting subgroup general considered being good prognosis.